These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 6380707)

  • 1. Selection of 9-beta-D-arabinofuranosyladenine-resistant human T-lymphoblasts with altered ribonucleotide reductase activity.
    Fridland A
    Cancer Res; 1984 Oct; 44(10):4328-32. PubMed ID: 6380707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of the mechanism of activation of 9-beta-D-arabinofuranosyladenine in human lymphoid cells using mutants deficient in nucleoside kinases.
    Verhoef V; Sarup J; Fridland A
    Cancer Res; 1981 Nov; 41(11 Pt 1):4478-83. PubMed ID: 6272978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unusual sensitivity to bleomycin and joint resistance to 9-beta-D-arabinofuranosyladenine and 1-beta-D-arabinofuranosylcytosine of mouse FM3A cell mutants with altered ribonucleotide reductase and thymidylate synthase.
    Ayusawa D; Iwata K; Seno T
    Cancer Res; 1983 Feb; 43(2):814-8. PubMed ID: 6184158
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selection and characterization of mutant S49 T-lymphoma cell lines resistant to phosphonoformic acid: evidence for inhibition of ribonucleotide reductase.
    Albert DA; Gudas LJ
    J Cell Physiol; 1986 May; 127(2):281-7. PubMed ID: 2939095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    White EL; Shaddix SC; Brockman RW; Bennett LL
    Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line.
    Månsson E; Spasokoukotskaja T; Sällström J; Eriksson S; Albertioni F
    Cancer Res; 1999 Dec; 59(23):5956-63. PubMed ID: 10606241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of ribonucleotide reductase by a new class of isoindole derivatives: drug synergism with cytarabine (Ara-C) and induction of cellular apoptosis.
    Nandy P; Lien EJ; Avramis VI
    Anticancer Res; 1999; 19(3A):1625-33. PubMed ID: 10470093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determinants of deoxyadenosine toxicity in hybrids between human T- and B- lymphoblasts as a model for the development of drug resistance in T-cell acute lymphoblastic leukemia.
    Kurtzberg J; Hershfield MS
    Cancer Res; 1985 Apr; 45(4):1579-86. PubMed ID: 3872167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolism and selective cytotoxicity of 9-beta-D-arabinofuranosylguanine in human lymphoblasts.
    Shewach DS; Daddona PE; Ashcraft E; Mitchell BS
    Cancer Res; 1985 Mar; 45(3):1008-14. PubMed ID: 3971358
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cross-resistance patterns in hydroxyurea-resistant leukemia L1210 cells.
    Carter GL; Cory JG
    Cancer Res; 1988 Oct; 48(20):5796-9. PubMed ID: 2844392
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukemia L1210 cell lines resistant to ribonucleotide reductase inhibitors.
    Cory JG; Carter GL
    Cancer Res; 1988 Feb; 48(4):839-43. PubMed ID: 3276399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Resistance to 9-beta-D-arabinofuranosyladenine in cultured leukemia L 1210 cells.
    Cass CE; Selner M; Phillips JR
    Cancer Res; 1983 Oct; 43(10):4791-8. PubMed ID: 6603904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased level of ribonucleotide reductase and associated resistance to aphidicolin in mouse FM3A cell mutants selected for simultaneous resistance to 9-beta-D-arabinofuranosyladenine and 1-beta-D-arabinofuranosylcytosine.
    Iwata K; Ayurawa D; Seno T
    Gan; 1982 Apr; 73(2):167-74. PubMed ID: 6811359
    [TBL] [Abstract][Full Text] [Related]  

  • 14. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
    Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relative cytotoxicity of 9-beta-D-arabinofuranosyladenine and 9-beta-D-arabinofuranosyladenine 5'-monophosphate.
    Juranka P; Chan VL
    Cancer Res; 1980 Nov; 40(11):4123-6. PubMed ID: 6162544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
    Parker WB; Shaddix SC; Chang CH; White EL; Rose LM; Brockman RW; Shortnacy AT; Montgomery JA; Secrist JA; Bennett LL
    Cancer Res; 1991 May; 51(9):2386-94. PubMed ID: 1707752
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Two approaches that increase the activity of analogs of adenine nucleosides in animal cells.
    Plunkett W; Cohen SS
    Cancer Res; 1975 Jun; 35(6):1547-54. PubMed ID: 1079475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of mouse leukemia L1210 cells resistant to the ribonucleotide reductase inhibitor 4-methyl-5-amino-1-formylisoquinoline thiosemicarbazone.
    Cory AH; Sato A; Thompson DP; Cory JG
    Oncol Res; 1996; 8(10-11):449-56. PubMed ID: 9114437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular mechanisms of drug resistance involving ribonucleotide reductase: hydroxyurea resistance in a series of clonally related mouse cell lines selected in the presence of increasing drug concentrations.
    Choy BK; McClarty GA; Chan AK; Thelander L; Wright JA
    Cancer Res; 1988 Apr; 48(8):2029-35. PubMed ID: 2832057
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.